A Phase 2 Evaluation of a Novel Co-Formulation of Pramlintide and Regular Insulin to Improve Postprandial Glycemic Control in Adults with Type 1 Diabetes (T1D)

Objective: Pramlintide co-administration, used in conjunction with prandial insulin, has substantial clinical benefits to improve post-prandial glucose excursions, glycemic variability (GV) and time in range (TIR), but is associated with an increased injection burden that adversely affects adherence...

Descripción completa

Detalles Bibliográficos
Autores principales: Edelman, Steven Victor, Conoscenti, Valentina, Junaidi, M Khaled, Close, Nicole, Sequeira, David, Nguyen, Anh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265936/
http://dx.doi.org/10.1210/jendso/bvab048.669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265936/
http://dx.doi.org/10.1210/jendso/bvab048.669

Ejemplares similares